Treatment of Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

What we are studying

This study is being done because standard chemotherapy for AR-ALL does not get rid of the cancer in all children with AR-ALL. The overall goal of Part I of this study is to collect information about Standard Risk Acute Lymphoblastic Leukemia (SR-ALL) and about the effects of the first phase of treatment, called Induction. The overall goal of Part II of this study is to collect information on the leukemia and the effects of different treatments. Phase III of this study is testing whether modifications in Maintenance therapy will improve outcomes while minimizing side effects. Side effects are unintended and unwanted results of treatment.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 1 - 10

Eligibility Criteria

  • Newly diagnosed with Acute Lymphoblastic Leukemia (ALL)
  • No previous chemotherapy for ALL or any previous cancer

What is involved

  • Part I (induction) lasts 4 weeks
  • Part II (Post-induction therapy) will last approximately 2 to 3 years
  • Part III (maintenance) will last between 2 to 3 years
  • Follow-Up will last about 10 years



Contact Information

Study Coordinator
Graham Keyes

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.